Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial comparing once-daily versus once-weekly setmelanotide in patients with MC4R-pathway genetic obesity already stable on daily treatment
NL-OMON53772Phase 3Active, not recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jan 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of setmelanotide in pro-opiomelanocortin deficiency, PCSK1 deficiency (PCSK1D), leptin receptor deficiency, Bardet–Biedl syndrome (BBS), sponsored by Rhythm Pharmaceuticals. Started Jan 2023; status: active, not recruiting.
02
Drugs
setmelanotide
03
Conditions
pro-opiomelanocortin deficiencyPCSK1 deficiency (PCSK1D)leptin receptor deficiencyBardet–Biedl syndrome (BBS)
Beyond the preview
Go deeper on NL-OMON53772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53772.